相关实验视频

Updated: Mar 3, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

晚期头角状细胞癌患者的息性放射治疗后连续免疫检查点抑制:一项回顾性队列研究

Atsuto Katano¹, Akiko Oka¹, Masanari Minamitani¹

¹Department of Radiology, The University of Tokyo Hospital, Tokyo 113-0033, Japan.

Molecular and clinical oncology

|March 2, 2026

概括

缓解性放射治疗 (RT) 后的连续免疫检查点抑制剂 (ICI) 治疗显著改善了晚期头支状细胞癌 (HNSCC) 的存活率. 更高的RT剂量也与这个患者群体的更好的结果相关.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
免疫治疗是一种免疫疗法.

背景情况:

先进的头角状细胞癌 (HNSCC) 往往对治愈治疗构成挑战.
息性放射治疗 (RT) 可以控制症状并改善患者的状况,从而有可能允许进行全身疗法.
在HNSCC中,RT和免疫检查点抑制剂 (ICI) 的最佳测序需要进一步研究.

研究的目的:

评估在高级HNSCC患者的息性RT后给予ICI治疗的临床结果.
为了比较接收RT后ICI (RT-ICI) 的患者和仅接收RT的患者 (RT组) 之间的生存率.

主要方法:

在东京大学医院治疗的高级HNSCC患者的回顾性审查 (2017年1月 - 2024年12月).
患者最初接受了息性RT,有些人随后在6个月内接受了ICI.
使用Kaplan-Meier和Cox比例危险模型分析的整体生存率 (OS) 和无进展生存率 (PFS).

主要成果:

在RT-ICI组显示了2年OS率为55.8%,而在RT组为5.7% (P<0.001).
在RT-ICI组中,PFS的中位数为12.7个月,两年PFS率为20.9%.
RT-ICI治疗,更高的RT剂量 (≥39 Gy) 和保持的性能状态是改善OS的独立预测因素.

结论:

息性RT后的连续ICI治疗与晚期HNSCC中改善的生存率有关.
更高的RT剂量也可能有助于更好的生存结果.
需要进一步的前性研究来证实这些发现,并优化治疗序列和剂量.

关键词:

头部和部状细胞癌瘤免疫检查点抑制剂免疫检查点抑制剂缓解性放射治疗是一种缓解性放射治疗.一个回顾性队列队列.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...